argenex (NASDAQ:ARGX) Price Target Raised to $932.00

argenex (NASDAQ:ARGX) had its target price lifted by Robert W. Baird from $867.00 to $932.00 in a research note released on Monday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Guggenheim raised their price target on argenex from $1,135.00 to $1,185.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Royal Bank Of Canada boosted their price objective on shares of argenex from $945.00 to $1,025.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Citigroup boosted their price target on shares of argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Wall Street Zen upgraded argenex from a “hold” rating to a “buy” rating in a report on Saturday, July 25th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research note on Thursday, June 11th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,056.89.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $882.56 on Monday. The company has a market cap of $55.21 billion, a price-to-earnings ratio of 33.89, a PEG ratio of 1.13 and a beta of 0.45. argenex has a one year low of $596.01 and a one year high of $953.58. The firm has a fifty day moving average price of $873.58 and a two-hundred day moving average price of $816.78.

argenex (NASDAQ:ARGX) last announced its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. The business had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. Equities research analysts expect that argenex will post 27.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Eastern Bank purchased a new position in argenex during the second quarter valued at $32,000. Sound Income Strategies LLC bought a new stake in argenex during the fourth quarter worth about $28,000. Whipplewood Advisors LLC purchased a new stake in argenex in the first quarter worth about $28,000. Sunbelt Securities Inc. bought a new position in shares of argenex during the third quarter valued at approximately $36,000. Finally, Axiom Investment Management LLC bought a new stake in shares of argenex in the 1st quarter worth approximately $50,000. Institutional investors own 60.32% of the company’s stock.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Forte Biosciences acquisition expands the autoimmune pipeline: argenx agreed to acquire Forte for approximately $2.2 billion, or $77 per Forte share in cash. The transaction would add Forte’s autoimmune drug candidate to argenx’s portfolio and could strengthen its long-term growth opportunities. Argenx signs agreement to buy Forte Biosciences for $2.2bn
• Positive Sentiment: Analysts raised their targets: Wedbush lifted its price target from $1,000 to $1,050 and assigned an “Outperform” rating. A separate Seeking Alpha analysis upgraded ARGX to “Buy” with a $1,050 target, citing continued VYVGART growth, additional label expansions, at-home administration and pipeline potential. Wedbush raises argenx price target argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go
• Positive Sentiment: Long-term earnings expectations improved: HC Wainwright maintained a “Buy” rating and raised its EPS forecasts for 2026 through 2030, including increases to $34.38 for 2027, $43.50 for 2028, $53.47 for 2029 and $64.39 for 2030. The revisions indicate stronger expected VYVGART-driven growth and pipeline contributions. HC Wainwright earnings estimate changes
• Neutral Sentiment: Relative performance remains in focus: Zacks compared argenx’s year-to-date performance with Agilent Technologies and the broader medical sector, but the report did not identify a new fundamental catalyst. Is Argenx Outperforming Other Medical Stocks This Year?
• Negative Sentiment: Deal scrutiny and valuation risks: A law firm is investigating whether Forte shareholders are receiving adequate consideration and whether the sale process was appropriate. Separately, analyses suggested ARGX could be fairly valued or as much as 15% above fair value after the Forte deal, raising concerns about acquisition execution and limited near-term upside. Forte Biosciences investor alert argenx could be 15% above fair value

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.